Yellow fever neutralizing antibody seroprevalence proportion and titers in previously vaccinated adults with chronic kidney disease

• Published in: Vaccine 2024-04, Vol.42 (11), p.2729-2732
• Main Authors: Cristina Martini Rodrigues, Camila, Caroline Ribeiro Sales, Amanda, Marli Christovam Sartori, Ana, de Souza Azevedo, Adriana, Maria Barbosa de Lima, Sheila, de Melo Picone, Camila, Keiko Sato, Paula, Nazareth Lara, Amanda, Takesaki Miyaji, Karina, Sérgio Azevedo, Luiz, Caldin, Bruno, Camera Pierrotti, Lígia, Heloisa Lopes, Marta
• Format: Article
• Language: English
• Subjects: Adult; Adults; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Chronic illnesses; Chronic kidney disease; Contraindications; Cross-Sectional Studies; Diabetes; Dialysis; Dilution; Education; Epidemics; Fever; Hemodialysis; Horseradish peroxidase; Humans; Kidney diseases; Kidneys; Neutralization; Neutralizing; Peroxidase; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - therapy; Seroepidemiologic Studies; Serology; seroprevalence; Statistical analysis; Transplants & implants; Vaccination; Vaccines; Vector-borne diseases; viruses; Yellow fever; Yellow Fever - prevention & control; Yellow Fever Vaccine; Yellow fever virus
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2024.03.029

Studies on yellow fever vaccine (YF) in chronic kidney disease (CKD) patients are scarce. This cross-sectional study aimed to evaluate YF neutralizing antibody seroprevalence and titers in previously vaccinated adults with CKD, on dialysis (D-CKD) or not (ND-CKD), compared to healthy persons. The micro Plaque Reduction Neutralization-Horseradish Peroxidase (μPRN-HP) test was used. Antibody titers were expressed as the reciprocal of the highest dilution that neutralized the challenge virus by 50 % (μPRN50). Seropositivity cut-off was set at ≥ 1:100. We included 153 participants: 46 ND-CKD, 50 D-CKD and 57 healthy adults. Median ages were 58.3, 55 and 52.2 years, respectively. Median time since YF vaccination was 22.3, 18.5 and 48.3 months respectively. There were no statistically significant differences in YF seroprevalence and neutralizing antibodies titers among groups: 100 % of ND-CKD; 96 % of D-CKD and 100 % of healthy participants were seropositive. Geometric mean titers (GMT) were 818.5, 683.0 and 665.5, respectively (p = 0.289).